166 related articles for article (PubMed ID: 34825020)
21. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects.
Raborn LN; Burke AB; Ebb DH; Collins MT; Kaban LB; Boyce AM
Osteoporos Int; 2021 Sep; 32(9):1889-1893. PubMed ID: 33772327
[TBL] [Abstract][Full Text] [Related]
22. Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report.
Kashii M; Ebina K; Kitaguchi K; Yoshikawa H
Bone Rep; 2020 Dec; 13():100288. PubMed ID: 32548215
[TBL] [Abstract][Full Text] [Related]
23. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
Pratt RM; West ML; Tennankore KK
Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
[TBL] [Abstract][Full Text] [Related]
24. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
26. The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review.
Inojosa AC; Mendes L; Bandeira L; Bandeira F
J Bone Metab; 2022 Nov; 29(4):217-223. PubMed ID: 36529864
[TBL] [Abstract][Full Text] [Related]
27. Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
Sydlik C; Dürr HR; Pozza SB; Weißenbacher C; Roeb J; Schmidt H
World J Pediatr; 2020 Oct; 16(5):520-527. PubMed ID: 32776272
[TBL] [Abstract][Full Text] [Related]
28. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
29. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
[TBL] [Abstract][Full Text] [Related]
30. Effects of Denosumab After Treatment Discontinuation : A Review of the Literature.
Iranikhah M; Deas C; Murphy P; Freeman MK
Consult Pharm; 2018 Mar; 33(3):142-151. PubMed ID: 29720299
[TBL] [Abstract][Full Text] [Related]
31. Should denosumab treatment for osteoporosis be continued indefinitely?
Noble JA; McKenna MJ; Crowley RK
Ther Adv Endocrinol Metab; 2021; 12():20420188211010052. PubMed ID: 34104392
[TBL] [Abstract][Full Text] [Related]
32. Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.
Jähn-Rickert K; Wölfel EM; Jobke B; Riedel C; Hellmich M; Werner M; McDonald MM; Busse B
Front Endocrinol (Lausanne); 2020; 11():250. PubMed ID: 32499755
[TBL] [Abstract][Full Text] [Related]
33. Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases.
Upfill-Brown A; Bukata S; Bernthal NM; Felsenfeld AL; Nelson SD; Singh A; Wesseling-Perry K; Eilber FC; Federman NC
JBMR Plus; 2019 Oct; 3(10):e10210. PubMed ID: 31687646
[TBL] [Abstract][Full Text] [Related]
34. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
35. Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
Anastasilakis AD; Trovas G; Balanika A; Polyzos SA; Makras P; Tournis S
J Clin Densitom; 2021; 24(2):338-340. PubMed ID: 33218880
[TBL] [Abstract][Full Text] [Related]
36. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
[TBL] [Abstract][Full Text] [Related]
37. Denosumab Treatment Does Not Halt Progression of Bone Lesions in Multicentric Carpotarsal Osteolysis Syndrome.
Lerman MA; Francavilla M; Waqar-Cowles L; Levine MA
JBMR Plus; 2023 May; 7(5):e10729. PubMed ID: 37197321
[TBL] [Abstract][Full Text] [Related]
38. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
Federman N; Brien EW; Narasimhan V; Dry SM; Sodhi M; Chawla SP
Paediatr Drugs; 2014 Feb; 16(1):21-8. PubMed ID: 24114694
[TBL] [Abstract][Full Text] [Related]
39. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature.
Luengo-Alonso G; Mellado-Romero M; Shemesh S; Ramos-Pascua L; Pretell-Mazzini J
Arch Orthop Trauma Surg; 2019 Oct; 139(10):1339-1349. PubMed ID: 30877429
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
